Alterations in the insulin/IGF-1 pathway, including reduced receptor expression and abnormal phosphorylation of proteins in the PI3K/Akt and RAS/RAF/MAPK pathways, have been identified in the brains of AD patients, suggesting a strong connection between metabolic dysfunction and neurodegeneration [133]. This evidence concerns the gene IGF1 and Alzheimer disease.